Enicepatide Phase 2 Signals Impress, But Tirzepatide HTA Ceiling Defines the Real Hurdle

Roche's Enicepatide Achieves Best-in-Disease Glycemic Control and Weight Loss

Roche's injectable GLP-1/GIP dual receptor agonist, enicepatide, acquired through Carmot Therapeutics, demonstrated significant and dose-dependent reductions in blood glucose and body weight in a 48-week Phase 2 clinical trial (CT-388-104) for patients with type 2 diabetes who are overweight or have obesity. Patients receiving the highest dose achieved an average HbA1c reduction of 2.65%, with 90% reaching the target of 6.5% or lower, and 62% achieving normal blood sugar levels (below 5.7%). Additionally, the drug spurred a 15.5% mean reduction in body weight without a plateau. The safety and tolerability profile was consistent with other incretin-based medicines, supporting its rapid advancement into Phase 3 studies.

• Enicepatide delivered "best-in-disease glycemic control" in the Phase 2 trial. Patients on the highest dose showed an average HbA1c reduction of 2.65% over 48 weeks. Critically, 90% of these patients achieved the diagnostic threshold for T2D (HbA1c ≤ 6.5%), and 62% reached normal blood sugar levels (HbA1c < 5.7%), highlighting its profound impact on glucose regulation.
• The trial demonstrated a substantial 15.5% mean reduction in body weight among patients treated with enicepatide, with Roche noting that this reduction showed no demonstrable plateau. This sustained weight loss, combined with the strong glycemic benefits, positions enicepatide as a potentially differentiated molecule for enhancing metabolic health.
• Enicepatide exhibited a safety and tolerability profile consistent with other incretin-based medicines, with a low discontinuation rate of 2% in the treatment arm compared to none in the placebo group. Based on these positive Phase 2 results, Roche is rapidly advancing the program, with two ongoing Phase 3 trials (ENITH-1 and ENITH-2) for chronic weight management and plans to start a late-stage study for glycemic control and cardiovascular outcomes in the first half of 2027.

Enicepatide's Phase 2 Data Shows Best-in-Disease Glycemic Control

The SURPASS-2 trial, a randomised Phase 3 study enrolling 1,879 adults with type 2 diabetes, evaluated tirzepatide (5, 10, and 15 mg) against semaglutide (1 mg) over 40 weeks. A post hoc analysis of this trial assessed attainment of both standard and intensive cardiometabolic targets. For standard targets, 34% of semaglutide-treated participants met three or more goals, compared with 42%, 53%, and 57% with tirzepatide 5, 10, and 15 mg, respectively. For intensive targets, the corresponding figures were 8% with semaglutide versus 15%, 20%, and 29% with tirzepatide. Tirzepatide increased the odds of achieving HbA1c below 53 mmol/mol (OR 1.50; 95% CI 1.12, 2.00), HbA1c below 48 mmol/mol (OR 1.88; 95% CI 1.49, 2.36), weight loss greater than 10% (OR 2.72; 95% CI 2.14, 3.47), weight loss greater than 15% (OR 3.86; 95% CI 2.69, 5.55), and the intensive blood pressure target (OR 1.45; 95% CI 1.17, 1.81).

A 5-year simulation study using the BRAVO diabetes model, extrapolating from the SURPASS-2 and SUSTAIN-4 trials, projected the long-term complication burden associated with tirzepatide, semaglutide, and insulin glargine. Under an optimistic scenario — in which 1-year treatment effects persisted — tirzepatide 15 mg was associated with a 5-year cardiovascular adverse event risk reduction (rate ratio 0.64; 95% CI 0.61–0.67) and microvascular composite risk reduction (rate ratio 0.67; 95% CI 0.64–0.70) versus insulin glargine. Semaglutide 1 mg showed corresponding rate ratios of 0.75 (95% CI 0.72–0.79) and 0.79 (95% CI 0.76–0.82). The 5-year risk reduction in diabetes-related complication events and mortality for tirzepatide 15 mg versus insulin glargine ranged from 49% to 10% under the optimistic scenario, reduced by 17%–33% under a conservative scenario.

A real-world retrospective cohort study conducted in the United Arab Emirates evaluated once-weekly subcutaneous semaglutide in 278 adults with type 2 diabetes over 12 months. Adjusted HbA1c decreased by -0.89% (95% CI -1.07 to -0.70) at 6 months and -0.71% (95% CI -0.91 to -0.50) at 12 months (both p < 0.001). Body weight decreased by -3.09 kg at 6 months and -4.77 kg at 12 months (p < 0.001), and systolic blood pressure decreased by -3.56 mmHg at 6 months (p = 0.007). At 12 months, 39% of patients achieved an HbA1c reduction of ≥1%, 43% achieved ≥5% weight loss, and 23% met the composite endpoint. Higher baseline HbA1c was identified as a predictor of glycemic response (OR 1.85; 95% CI 1.26 to 2.88).

Biased Agonism: Enicepatide's Bold Bid for Metabolic Leadership

Roche's recent announcement regarding its injectable GLP-1/GIP dual receptor agonist, enicepatide (CT-388), marks a significant stride in addressing the global epidemics of type 2 diabetes and obesity. The Phase 2 clinical trial results are compelling, showcasing an average HbA1c reduction of 2.65% at the highest dose, with a remarkable 90% of patients achieving target glycemic control and 62% reaching normal blood sugar levels. Beyond glucose management, enicepatide delivered substantial and sustained weight loss, averaging 15.5% without a plateau, a critical outcome for patients struggling with obesity.

This strong efficacy profile is underpinned by enicepatide's unique mechanism as a signaling-biased dual GLP-1R/GIPR agonist. Research indicates that this biased agonism may yield greater weight loss and better glycemic control compared to unbiased approaches, offering a potential differentiator in a crowded market. Furthermore, the drug's safety and tolerability profile was consistent with other incretin-based therapies, a crucial factor for chronic treatment. Existing evidence for the GLP-1/GIP agonist class even suggests a protective role against gallstone-related complications, which could further bolster confidence in its long-term safety.

The rapid advancement of enicepatide into Phase 3 studies underscores Roche's aggressive strategy and confidence in this asset, validating its acquisition of Carmot Therapeutics. This move positions enicepatide as a formidable contender, poised to challenge established players and potentially reshape treatment paradigms for metabolic diseases. However, the path forward is not without its considerations. The competitive landscape for GLP-1/GIP agonists is intense, demanding that enicepatide demonstrate sustained superiority or a distinct advantage in larger Phase 3 trials to secure significant market share. While the biased agonism mechanism is promising, its full clinical benefit over other dual agonists requires robust confirmation. Additionally, as an injectable, once-weekly administration, patient adherence will be a factor, especially as the market may see the emergence of oral formulations or less frequent dosing regimens. Nevertheless, enicepatide's impressive Phase 2 data suggests a powerful new option is on the horizon, with the potential to significantly improve patient outcomes.